Clinical Trial Update: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) [Phase 2]

View source ↗

Summary

AbbVie’s ABT-122 Phase 2 trial in active psoriatic arthritis completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ABT-122

Snippet

Sponsor: AbbVie | Conditions: Psoriatic Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2017-08-04